{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:21:18Z","timestamp":1790774478133,"version":"4.1.0"},"reference-count":143,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012353","name":"Deutschen Konsortium f\u00fcr Translationale Krebsforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012353","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["441891347"],"award-info":[{"award-number":["441891347"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["259373024"],"award-info":[{"award-number":["259373024"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["256073931"],"award-info":[{"award-number":["256073931"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2026,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Epigenetic modifications such as DNA methylation play a fundamental role in oncogenesis and the progression of neoplasms neoplasias. DNA methyltransferase inhibitors (DNMTi) constitute a family of therapeutic agents that impede the methylation at the 5\u2010position on cytosine nucleotides, thereby modulating the epigenetic regulation of tumor suppressor genes, oncogenes, and other key regulatory genes. The first\u2010generation DNMTi azacitidine and decitabine have demonstrated substantial efficacy in the treatment of medically non\u2010fit, older patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy (IC), by virtue of their favorable safety profile. Despite these clinical achievements, however, single\u2010agent DNMTi treatment has faced challenges such as limited, non\u2010durable response rates and remissions as well as the emergence of secondary resistance. These limitations have driven broad efforts to identify more effective, dual treatment combinations, such as now attained with the DNMTi\u2010BCL\u20102 (B\u2010cell lymphoma 2) inhibitor combination. This review aims to provide a comprehensive overview and analysis of the pivotal role of DNMTi in both mono\u2010 and combination therapies for myeloid malignancies over the last 40\u2009years, while also exploring their potential applicability in lymphoid malignancies. Additionally, this review assesses the therapeutic potential of DNMTi in the management of solid tumors. Through these discussions, we intend to enhance the understanding of the mechanistic and therapeutic implications of DNMTi across a diverse array of malignancies.<\/jats:p>","DOI":"10.1002\/ijc.70197","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T05:10:59Z","timestamp":1762578659000},"page":"433-461","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["<scp>DNA<\/scp>\n                    methyltransferase inhibitors in hematological malignancies and solid tumors"],"prefix":"10.1002","volume":"158","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1522-211X","authenticated-orcid":false,"given":"Valentin","family":"Wenger","sequence":"first","affiliation":[{"name":"Department of Medicine I (Division of Hematology, Oncology and Stem Cell Transplantation) University of Freiburg Medical Center, Faculty of Medicine  Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia\u2010Manero","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Zeiser","sequence":"additional","affiliation":[{"name":"Department of Medicine I (Division of Hematology, Oncology and Stem Cell Transplantation) University of Freiburg Medical Center, Faculty of Medicine  Freiburg Germany"},{"name":"German Cancer Consortium (DKTK), Partner Site Freiburg, a Partnership Between DKFZ and University of Freiburg Medical Center  Freiburg Germany"},{"name":"Signaling Research Centres BIOSS and CIBSS \u2013 Centre for Integrative Biological Signaling Studies, University of Freiburg  Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1186-1650","authenticated-orcid":false,"given":"Michael","family":"L\u00fcbbert","sequence":"additional","affiliation":[{"name":"Department of Medicine I (Division of Hematology, Oncology and Stem Cell Transplantation) University of Freiburg Medical Center, Faculty of Medicine  Freiburg Germany"},{"name":"German Cancer Consortium (DKTK), Partner Site Freiburg, a Partnership Between DKFZ and University of Freiburg Medical Center  Freiburg Germany"},{"name":"German Society of Hematology and Medical Oncology (DGHO) Working Group \u2018Clinical and Translational Epigenetics\u2019  Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-1059"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a018200"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ydbio.2016.06.005"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97117"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113016"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.562447"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.351444.123"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.2217\/epi.09.33"},{"key":"e_1_2_7_10_1","first-page":"123","article-title":"THE activity of a new antimetabolite, 5\u2010azacytidine, against lymphoid LEUKAEMIA in AK mice","volume":"11","author":"Sorm F","year":"1964","journal-title":"Neoplasma"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02135399"},{"key":"e_1_2_7_12_1","first-page":"625","article-title":"Microbiological production of 5\u2010azacytidine. II. Isolation and chemical structure","volume":"6","author":"Bergy ME","year":"1966","journal-title":"Antimicrob Agents Chemother (Bethesda)"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-0458"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01218-0"},{"issue":"11","key":"e_1_2_7_15_1","first-page":"2760","article-title":"Cytotoxicity and mode of action of 5\u2010azacytidine on L1210 leukemia","volume":"30","author":"Li LH","year":"1970","journal-title":"Cancer Res"},{"issue":"11","key":"e_1_2_7_16_1","first-page":"2770","article-title":"Phase specificity of 5\u2010azacytidine against mammalian cells in tissue culture","volume":"30","author":"Li LH","year":"1970","journal-title":"Cancer Res"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(76)90338-5"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V57.1.182.182"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-85-2-237"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(80)90237-8"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/9.12.2933"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-2836(82)90395-3"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401719"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra023075"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrg816"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2020.11.008"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-54490-3_19"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-07-604512"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/10781552241238979"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.04.117"},{"key":"e_1_2_7_31_1","first-page":"68","volume-title":"Seminars in Cancer Biology","author":"Flotho C","year":"2018"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34377"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-06-163246"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20184576"},{"issue":"5","key":"e_1_2_7_35_1","first-page":"493","article-title":"5\u2010azacytidine in childhood leukemia","volume":"18","author":"Hrodek O","year":"1971","journal-title":"Neoplasma"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V42.3.359.359"},{"key":"e_1_2_7_37_1","first-page":"816","article-title":"Low dose continuous infusion azacytidine is an effective therapy for patients with myelodysplastic syndromes, a study of cancer and leukemia group B","volume":"116","author":"Silverman L","year":"1990","journal-title":"J Cancer Res Clin Oncol"},{"key":"e_1_2_7_38_1","unstructured":"SilvermanL HollandJ DemakosE.Azacitidine (AZA C) in myelodysplastic syndromes (MDS). CALGB Studies. 1993; 8421."},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.04.044"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270004271947"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70003-8"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.8329"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-621664"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.306"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-879866"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004444"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02619"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/0163-7258(85)90052-X"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21792"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.9245"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.9429"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30182-0"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30024-9"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00273-9"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-184851"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129876"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.048231"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00437"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200034"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-788497"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30576-4"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31138"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30029-8"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010179"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012062"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00338-1"},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004143"},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19741"},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00249-x"},{"key":"e_1_2_7_70_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS7077"},{"key":"e_1_2_7_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00375-1"},{"key":"e_1_2_7_72_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.7212"},{"key":"e_1_2_7_73_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24198"},{"key":"e_1_2_7_74_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25500"},{"key":"e_1_2_7_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.06.016"},{"key":"e_1_2_7_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-377044"},{"key":"e_1_2_7_77_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-249474"},{"key":"e_1_2_7_78_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002544"},{"key":"e_1_2_7_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.05.026"},{"key":"e_1_2_7_80_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.234"},{"key":"e_1_2_7_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30580-1"},{"key":"e_1_2_7_82_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.222"},{"key":"e_1_2_7_83_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.7"},{"key":"e_1_2_7_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.12.016"},{"key":"e_1_2_7_85_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3185-5"},{"key":"e_1_2_7_86_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19007"},{"key":"e_1_2_7_87_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26683-0"},{"key":"e_1_2_7_88_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1228927"},{"key":"e_1_2_7_89_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.242826"},{"key":"e_1_2_7_90_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010484"},{"key":"e_1_2_7_91_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-012-1537-8"},{"key":"e_1_2_7_92_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-143200"},{"key":"e_1_2_7_93_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0233-1"},{"issue":"4","key":"e_1_2_7_94_1","article-title":"Safety and efficacy: clinical experience of Venetoclax in combination with hypomethylating agents in both newly diagnosed and relapsed\/refractory advanced myeloid malignancies","volume":"5","author":"Feld J","year":"2021","journal-title":"Hema"},{"key":"e_1_2_7_95_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971"},{"key":"e_1_2_7_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00216-2"},{"key":"e_1_2_7_97_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01053"},{"key":"e_1_2_7_98_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-019-0739-5"},{"key":"e_1_2_7_99_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1612262113"},{"key":"e_1_2_7_100_1","article-title":"Vitamin C supplementation in patients with clonal cytopenia of undetermined significance or low\u2010risk myeloid malignancies: results from EVI\u20102, randomized, placebo\u2010controlled phase 2 study","author":"Mikkelsen S","year":"2024","journal-title":"EHA Library"},{"key":"e_1_2_7_101_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2139"},{"key":"e_1_2_7_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2024.107480"},{"key":"e_1_2_7_103_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30533"},{"key":"e_1_2_7_104_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.3102"},{"key":"e_1_2_7_105_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117344"},{"key":"e_1_2_7_106_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014586"},{"key":"e_1_2_7_107_1","first-page":"361","article-title":"Midostaurin added to 10\u2010day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome","volume":"104","author":"Huls G","year":"2024","journal-title":"Ann Hematol"},{"key":"e_1_2_7_108_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002846"},{"key":"e_1_2_7_109_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018023689"},{"key":"e_1_2_7_110_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.2510"},{"key":"e_1_2_7_111_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature07884"},{"key":"e_1_2_7_112_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01125-4"},{"key":"e_1_2_7_113_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007334"},{"key":"e_1_2_7_114_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02341"},{"key":"e_1_2_7_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00403-3"},{"key":"e_1_2_7_116_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00333-2"},{"key":"e_1_2_7_117_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005487"},{"key":"e_1_2_7_118_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006138"},{"key":"e_1_2_7_119_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17689"},{"key":"e_1_2_7_120_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005240"},{"key":"e_1_2_7_121_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5615"},{"key":"e_1_2_7_122_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08213.x"},{"key":"e_1_2_7_123_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011679"},{"key":"e_1_2_7_124_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199704000-00008"},{"key":"e_1_2_7_125_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006388031954"},{"key":"e_1_2_7_126_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-11-0214"},{"key":"e_1_2_7_127_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.29.15_suppl.5011"},{"key":"e_1_2_7_128_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-3909"},{"key":"e_1_2_7_129_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1961"},{"key":"e_1_2_7_130_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1638"},{"key":"e_1_2_7_131_1","doi-asserted-by":"publisher","DOI":"10.1080\/15592294.2021.1940644"},{"key":"e_1_2_7_132_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-0402"},{"key":"e_1_2_7_133_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-50749-1"},{"key":"e_1_2_7_134_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-018-0988-8"},{"issue":"3","key":"e_1_2_7_135_1","first-page":"413","article-title":"Phase I study of 5\u2010azacytidine (NSC\u2010102816)","volume":"56","author":"Weiss AJ","year":"1972","journal-title":"Cancer Chemother Rep"},{"issue":"1","key":"e_1_2_7_136_1","first-page":"55","article-title":"Phase II study of 5\u2010azacytidine in solid tumors","volume":"61","author":"Weiss AJ","year":"1977","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_7_137_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1729"},{"key":"e_1_2_7_138_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS23-PO1-18-04"},{"key":"e_1_2_7_139_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0421"},{"key":"e_1_2_7_140_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34845"},{"key":"e_1_2_7_141_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.9560"},{"key":"e_1_2_7_142_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025834"},{"key":"e_1_2_7_143_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027217"},{"key":"e_1_2_7_144_1","doi-asserted-by":"crossref","unstructured":"Efficace Fabio et al. \u201c10\u2010day decitabine versus intensive chemotherapy followed by transplantation in fit AML patients aged \u2265 60 years: health\u2010related quality of life outcomes of the randomized phase III trial AML21 of the EORTC Leukemia Group Gimema Celg and Gmds\u2010SG.\u201d (2022): 1281\u20101283.","DOI":"10.1182\/blood-2022-166544"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.70197","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T08:49:21Z","timestamp":1763542161000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.70197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":143,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,15]]}},"alternative-id":["10.1002\/ijc.70197"],"URL":"https:\/\/doi.org\/10.1002\/ijc.70197","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"2025-07-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}